Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes.
Author
Goncalves, I.
Bengtsson, E.
Colhoun, H. M.
Shore, Angela
Palombo, C.
Natali, A.
Edsfeldt, A.
Dunér, P.
Fredrikson, G. N.
Björkbacka, H.
Östling, G.
Aizawa, Kunihiko
Casanova, Francesco
Persson, M.
Gooding, Kim
Strain, David
Khan, F.
Looker, H. C.
Adams, F.
Belch, J.
Pinnoli, S.
Venturi, E.
Kozakova, M.
Gan, L.-M.
Schnecke, V.
Nilsson, J.
Date
2015-07Journal
Arteriosclerosis, thrombosis, and vascular biologyType
Journal ArticleResearch Support, Non-U.S. Gov't
Publisher
American Heart AssociationDOI
10.1161/ATVBAHA.115.305631Rights
Archived with thanks to Arteriosclerosis, thrombosis, and vascular biologyMetadata
Show full item recordAbstract
Matrix metalloproteinases (MMPs) degrade extracellular matrix proteins and play important roles in development and tissue repair. They have also been shown to have both protective and pathogenic effects in atherosclerosis, and experimental studies have suggested that MMP-12 contributes to plaque growth and destabilization. The objective of this study was to investigate the associations between circulating MMPs, atherosclerosis burden, and incidence of cardiovascular disease with a particular focus on type 2 diabetes mellitus.